All In Biotech

Drug Trial Radar · NCT00910455

Study of SRX246 Capsules in Healthy Adult Volunteers

Phase I, Double-Blind, Placebo-Controlled, Ascending, Single-Dose, Safety, Tolerability and Pharmacokinetic Study of SRX246 Capsules in Healthy Adult Volunteers

Last checked: Nov 19, 2026Latest source record: Mar 17, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

49

Actual

Start

May 2009

Primary completion

Sep 2009

Study completion Sep 2009

Sponsor

Lead sponsor
Azevan PharmaceuticalsIndustry
Sponsor type
Industry
First posted
May 29, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Single group
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is the first study of SRX246 in humans, and is being conducted to begin to establish a safety profile of orally administered SRX246.

Conditions

  • Healthy

Interventions

  • SRX246Drug

    single oral dose of SRX246 capsule

  • PlaceboDrug

    Single oral dose of placebo capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess safety and tolerability of SRX246 at single doses ranging between 20 and 360 mgTime frame: 24 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Advanced Biomedical Research

    Hackensack, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.